Advancing Drug Safety in Drug Development: Bridging Computational Predictions for Enhanced Toxicity Prediction
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
The attrition rate of drugs in clinical trials is generally quite high, with estimates suggesting that approximately 90% of drugs fail to make it through the process. The identification of unexpected toxicity issues during preclinical stages is a significant factor contributing to this high rate of failure. These issues can have a major impact on the success of a drug and must be carefully considered throughout the development process. These late-stage rejections or withdrawals of drug candidates significantly increase the costs associated with drug development, particularly when toxicity is detected during clinical trials or after market release. Understanding drug-biological target interactions is essential for evaluating compound toxicity and safety, as well as predicting therapeutic effects and potential off-target effects that could lead to toxicity. This will enable scientists to predict and assess the safety profiles of drug candidates more accurately. Evaluation of toxicity and safety is a critical aspect of drug development, and biomolecules, particularly proteins, play vital roles in complex biological networks and often serve as targets for various chemicals. Therefore, a better understanding of these interactions is crucial for the advancement of drug development. The development of computational methods for evaluating protein-ligand interactions and predicting toxicity is emerging as a promising approach that adheres to the 3Rs principles (replace, reduce, and refine) and has garnered significant attention in recent years. In this review, we present a thorough examination of the latest breakthroughs in drug toxicity prediction, highlighting the significance of drug-target binding affinity in anticipating and mitigating possible adverse effects. In doing so, we aim to contribute to the development of more effective and secure drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Advancing drug safety assessment relies on bridging the translation gap between animal toxicology findings and clinical outcomes, a challenge with far-reaching consequences for R&D efficiency, regulatory success and patient safety (Waring et al., 2015; Amorim et al., 2024).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Amorim et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
XGBoost: A Scalable Tree Boosting System
Chen, T., & Guestrin, C. (2016) · Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining · doi:10.1145/2939672.2939785 · Cited by 54,569 · cited 1×
“Using an ensemble approach that leverages DNN, RF, and extreme Gradient Boosting (XGBoost), 62 they also examined the contribution of each input fingerprint to the prediction output, thus gaining insight into warning substructures that might be indicative of the cardiotoxicity of the input compound.”
MethodDrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
PubChem in 2021: new data content and improved web interfaces
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa971 · Cited by 3,953
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac956 · Cited by 3,443
Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab255 · Cited by 2,857
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., Mutowo, P., Atkinson, F., Bellis, L. J., Cibrián-Uhalte, E., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1074 · Cited by 2,330
KEGG for representation and analysis of molecular networks involving diseases and drugs
Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M., & Hirakawa, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp896 · Cited by 2,322
SchNet – A deep learning architecture for molecules and materials
Schütt, K. T., Sauceda, H. E., Kindermans, P.-J., Tkatchenko, A., & Müller, K.-R. (2018) · The Journal of Chemical Physics · doi:10.1063/1.5019779 · Cited by 2,217
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl999 · Cited by 2,124
Research works printed but not linked: 1
- Feng Q.; Dueva E.; Cherkasov A.; Ester M. PADME: A Deep Learning-Based Framework for Drug-Target Interaction Prediction. arXiv [cs.LG], 2018.
Cited by
Artificial intelligence revolution in drug discovery: A paradigm shift in pharmaceutical innovation
Jarallah, S. J., Almughem, F. A., Alhumaid, N. K., Fayez, N. A., Alradwan, I. A., Alsulami, K. A., Tawfik, E. A., & Alshehri, A. A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125789 · Cited by 93
Artificial intelligence (AI) in drug design and discovery: A comprehensive review
Bhat, A. R., & Ahmed, S. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100049 · Cited by 76
Sohn, A., Park, J., Kim, W., Yoon, Y., Lee, S., Ji, J., & Kim, H. (2024) · Toxics · doi:10.3390/toxics12110822 · Cited by 68
“These developments collectively lead to a more efficient and ethical strategy in drug development, reducing the probability of late-stage failures caused by unanticipated toxicity [2,5,49,82,87].”
Overcoming Barriers in Cancer Biology Research: Current Limitations and Solutions
(2025) · doi:10.3390/cancers17132102 · Cited by 44
“However, they may not always accurately predict drug responses in humans because of species-specific differences in pharmacology and safety, and their generation and maintenance can be time-consuming and expensive [13–15].”
AI in fungal drug development: opportunities, challenges, and future outlook
Li, Y., Qiao, Y., Ma, Y., Xue, P., & Ding, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1610743 · Cited by 42
Metadata
- Authors
- Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S.
- Affiliations
- Centro de Neurociências e Biologia Celular (PT)
- CNC-UC─Center for Neuroscience and Cell Biology, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal
- Corresponding author
- Moreira, Irina S.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-05-17
- Volume
- 37
- Issue
- 6
- Pages
- 827-849
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- PMC
- PMC11187637
- OpenAlex
- W4397001794
- Cited by
- 132
- References
- 140
- Citations by year
- 2026: 69 · 2025: 56 · 2024: 7
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Chemical Research in Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Regional Development Fund
- Funda??o para a Ci?ncia e a Tecnologia (DSAIPA/DS/0118/2020, LA/P/0058/2020, SFRH/BD/144966/2019, UIDB/04539/2020, UIDP/04539/2020)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- drug toxicity prediction, drug safety, drug development attrition, protein-ligand interactions, drug binding affinity, off-target effects, computational toxicology, 3Rs, preclinical toxicity testing
- MeSH terms
- Drug Development, Animals, Humans, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.